Hepatoprotective effect of herb formula KIOM2012H against nonalcoholic fatty liver disease

Nutrients

Volumn 7, Issue 4, 2015, Pages 2440-2455

  Park, Hwayong ^a   Hwang, Youn Hwan ^a   Kim, Dong Gun ^a   Jeon, Jongwook ^a   Ma, Jin Yeul ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Fatty acid; Herbal medicine; Lipid; Nonalcoholic fatty liver disease

Indexed keywords

ADIPOPHILIN; ALANINE AMINOTRANSFERASE; CD36 ANTIGEN; FATTY ACID; FATTY ACID SYNTHASE; HERBACEOUS AGENT; KIOM2012H AGENT; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; TRIACYLGLYCEROL; UBIQUITIN C; UNCLASSIFIED DRUG; PLANT MEDICINAL PRODUCT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCTIUM LAPPA; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID TRANSPORT; FLOW CYTOMETRY; GENE EXPRESSION; GINGER; GLYCYRRHIZA URALENSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPID STORAGE; LIVER PROTECTION; MAGNOLIA OFFICINALIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROFLUOROMETRY; TRANSCRIPTION REGULATION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HEP-G2 CELL LINE; LIPID DIET; LIPOGENESIS; LIVER; LIVER CELL; MEDICINAL PLANT; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY;

ANIMALIA; MUS;

ANIMALS; CELL SURVIVAL; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; PLANT PREPARATIONS; PLANTS, MEDICINAL; TRIGLYCERIDES;

EID: 84927949136     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7042440     Document Type: Article

References (38)

1. Adams, L.A.; Angulo, P.; Lindor, K.D. Nonalcoholic fatty liver disease. Can. Med. Assoc. J. 2005, 172, 899-905.
2. Bedogni, G.; Nobili, V.; Tiribelli, C. Epidemiology of fatty liver: An update. World J. Gastroenterol. 2014, 20, 9050-9054.
3. Younossi, Z.M.; Stepanova, M.; Afendy, M.; Fang, Y.; Younossi, Y.; Mir, H.; Srishord, M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011, 9, 524-530.
4. Schwimmer, J.B.; Deutsch, R.; Kahen, T.; Lavine, J.E.; Stanley, C.; Behling, C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118, 1388-1393.
5. Than, N.N.; Newsome, P.N. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015, 239, 192-202.
6. Donnelly, K.L.; Smith, C.I.; Schwarzenberg, S.J.; Jessurun, J.; Boldt, M.D.; Parks, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1343-1351.
7. Tarantino, G.; Scopacasa, F.; Colao, A.; Capone, D.; Tarantino, M.; Grimaldi, E.; Savastano, S. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. World J. Gastroenterol. 2011, 17, 5280-5288.
8. Begriche, K.; Igoudjil, A.; Pessayre, D.; Fromenty, B. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion 2006, 6, 1-28.
9. Tarantino, G.; Colao, A.; Capone, D.; Conca, P.; Tarantino, M.; Grimaldi, E.; Chianese, D.; Finelli, C.; Contaldo, F.; Scopacasa, F.; et al. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J. Biol. Regul. Homeost. Agents 2011, 25, 47-56.
10. Tamura, S.; Shimomura, I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1139-1142.
11. Awale, S.; Lu, J.; Kalauni, S.K.; Kurashima, Y.; Tezuka, Y.; Kadota, S.; Esumi, H. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006, 66, 1751-1757.
12. Hyam, S.R.; Lee, I.A.; Gu, W.; Kim, K.A.; Jeong, J.J.; Jang, S.E.; Han, M.J.; Kim, D.H. Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages. Eur. J. Pharmacol. 2013, 708, 21-29.
13. Tian, X.; Guo, L.P.; Hu, X.L.; Huang, J.; Fan, Y.H.; Ren, T.S.; Zhao, Q.C. Protective effects of Arctium lappa L. roots against hydrogen peroxide-induced cell injury and potential mechanisms in SH-SY5Y cells. Cell. Mol. Neurobiol. 2014, doi:10.1007/s10571-014-0129-7.
14. Shin, Y.W.; Bae, E.A.; Lee, B.; Lee, S.H.; Kim, J.A.; Kim, Y.S.; Kim, D.H. In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components. Planta Med. 2007, 73, 257-261.
15. Seon, M.R.; Park, S.Y.; Kwon, S.J.; Lim, S.S.; Choi, H.J.; Park, H.; Lim, D.Y.; Kim, J.S.; Lee, C.H.; Kim, J.; et al. Hexane/ethanol extract of Glycyrrhiza uralensis and its active compound isoangustone A induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells. J. Nutr. Biochem. 2012, 23, 85-92.
16. Adianti, M.; Aoki, C.; Komoto, M.; Deng, L.; Shoji, I.; Wahyuni, T.S.; Lusida, M.I.; Soetjipto; Fuchino, H.; Kawahara, N.; et al. Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. Microbiol. Immunol. 2014, 58, 180-187.
17. Fu, Y.; Chen, J.; Li, Y.J.; Zheng, Y.F.; Li, P. Antioxidant and anti-inflammatory activities of six flavonoids separated from licorice. Food Chem. 2013, 141, 1063-1071.
18. Lin, A.; Liu, Y.; Huang, Y.; Sun, J.; Wu, Z.; Zhang, X.; Ping, Q. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int. J. Pharm. 2008, 359, 247-253.
19. Seo, M.S.; Hong, S.W.; Yeon, S.H.; Kim, Y.M.; Um, K.A.; Kim, J.H.; Kim, H.J.; Chang, K.C.; Park, S.W. Magnolia officinalis attenuates free fatty acid-induced lipogenesis via AMPK phosphorylation in hepatocytes. J. Ethnopharmacol. 2014, 157, 140-148.
20. Yin, H.Q.; Je, Y.T.; Kim, Y.C.; Shin, Y.K.; Sung, S.; Lee, K.; Jeong, G.S.; Kim, Y.C.; Lee, B.H. Magnolia officinalis reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element-binding protein-1c. J. Pharmacol. Sci. 2009, 109, 486-495.
21. Lei, L.; Liu, Y.; Wang, X.; Jiao, R.; Ma, K.Y.; Li, Y.M.; Wang, L.; Man, S.W.; Sang, S.; Huang, Y.; et al. Plasma cholesterol-lowering activity of gingerol- and shogaol-enriched extract is mediated by increasing sterol excretion. J. Agric. Food Chem. 2014, 62, 10515-10521.
22. Nammi, S.; Sreemantula, S.; Roufogalis, B.D. Protective effects of ethanolic extract of Zingiber officinale rhizome on the development of metabolic syndrome in high-fat diet-fed rats. Basic Clin. Pharmacol. Toxicol. 2009, 104, 366-373.
23. Fuhrman, B.; Rosenblat, M.; Hayek, T.; Coleman, R.; Aviram, M. Ginger extract consumption reduces plasma cholesterol, inhibits LDL oxidation and attenuates development of atherosclerosis in atherosclerotic, apolipoprotein E-deficient mice. J. Nutr. 2000, 130, 1124-1131.
24. Yim, N.H.; Cho, W.K.; Lee, J.H.; Jung, Y.P.; Yang, H.J.; Ma, J.Y. HRT, Herbal formula, induces G(2)/M cell cycle arrest and apoptosis via suppressing Akt signaling pathway in human colon cancer cells. Evid. Based Complement. Altern. Med. 2012, 2012, 871893, doi:10.1155/2012/871893.
25. Greenspan, P.; Fowler, S.D. Spectrofluorometric studies of the lipid probe, Nile Red. J. Lipid Res. 1985, 26, 781-789.
26. McMillian, M.K.; Grant, E.R.; Zhong, Z.; Parker, J.B.; Li, L.; Zivin, R.A.; Burczynski, M.E.; Johnson, M.D. Nile Red binding to HepG2 cells: An improved assay for in vitro studies of hepatosteatosis. In Vitro Mol. Toxicol. 2001, 14, 177-190.
27. Song, K.H.; Chiang, J.Y. Glucagon and cAMP inhibit cholesterol 7α-hydroxylase (CYP7A1) gene expression in human hepatocytes: Discordant regulation of bile acid synthesis and gluconeogenesis. Hepatology 2006, 43, 117-125.
28. Erickson, S.K. Nonalcoholic fatty liver disease. J. Lipid Res. 2009, 50, 412-416.
29. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Investig. 2004, 114, 147-152.
30. Grefhorst, A.; Elzinga, B.M.; Voshol, P.J.; Plösch, T.; Kok, T.; Bloks, V.W.; van der Sluijs, F.H.; Havekes, L.M.; Romijn, J.A.; Verkade, H.J.; et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277, 34182-34190.
31. Greco, D.; Kotronen, A.; Westerbacka, J.; Puig, O.; Arkkila, P.; Kiviluoto, T.; Laitinen, S.; Kolak, M.; Fisher, R.M.; Hamsten, A.; et al. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G1281-G1287.
32. Miquilena-Colina, M.E.; Lima-Cabello, E.; Sánchez-Campos, S.; García-Mediavilla, M.V.; Fernández-Bermejo, M.; Lozano-Rodríguez, T.; Vargas-Castrillón, J.; Buqué, X.; Ochoa, B.; Aspichueta, P.; et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 2011, 60, 1394-1402.
33. Zhou, J.; Febbraio, M.; Wada, T.; Zhai, Y.; Kuruba, R.; He, J.; Lee, J.H.; Khadem, S.; Ren, S.; Li, S.; et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARγ in promoting steatosis. Gastroenterology 2008, 134, 556-567.
34. Liang, L.; Zhao, M.; Xu, Z.; Yokoyama, K.K.; Li, T. Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DF45)-like effector family. Biochem. J. 2003, 370, 195-203.
35. Keller, P.; Petrie, J.T.; de Rose, P.; Gerin, I.; Wright, W.S.; Chiang, S.H.; Nielsen, A.R.; Fischer, C.P.; Pedersen, B.K.; MacDougald, O.A. Fat-specific protein 27 regulates storage of triacylglycerol. J. Biol. Chem. 2008, 283, 14355-14365.
36. Puri, V.; Konda, S.; Ranjit, S.; Aouadi, M.; Chawla, A.; Chouinard, M.; Chakladar, A.; Czech, M.P. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. J. Biol. Chem. 2007, 282, 34213-34218.
37. Van Rossum, T.G.; Vulto, A.G.; de Man, R.A.; Brouwer, J.T.; Schalm, S.W. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment. Pharmacol. Ther. 1998, 12, 199-205.
38. Okamoto, M.; Irii, H.; Tahara, Y.; Ishii, H.; Hirao, A.; Udagawa, H.; Hiramoto, M.; Yasuda, K.; Takanishi, A.; Shibata, S.; et al. Synthesis of a new [6]-gingerol analogue and its protective effect with respect to the development of metabolic syndrome in mice fed a high-fat diet. J. Med. Chem. 2011, 54, 6295-6304.